Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Vascular determinants of cancer cell fate and immune regulation in brain metastasis

Project description

Vascular control of brain metastasis

Metastasis occurs when cancer cells detach from a primary tumour, enter the circulation and colonise distant organs. This process requires that cancer cells adapt to entirely new microenvironments. In brain metastasis, cancer cells must cross the highly selective blood-brain barrier and interact with specialised vascular, immune and neural cells. The working hypothesis of the ERC-funded METAVASC project is that the brain vasculature acts as an active regulator of metastatic progression. Using advanced techniques and functional in vivo studies, researchers will investigate how the brain’s vascular components support early cancer cell survival and later immune cell recruitment. Project findings will support the design of novel translational strategies to prevent and treat brain metastasis.

Objective

Brain metastasis (BrM) is one of the deadliest cancer complications, affecting 30-40% of patients. When cancer cells migrate from the primary tumor to the brain, they face the critical challenge of adapting to an entirely new microenvironment. This includes various tissue-resident cell types, a distinct extracellular matrix composition, and more importantly, the challenge of traversing the multiple layers constituting the blood-brain barrier (BBB). The BBB – composed of the endothelial cells, mural cells, and associated microglia and neurons – not only serves as the initial gateway for cancer cells during the early stages of metastatic colonization but also for recruited immune cells, such as cytotoxic T cells, in advanced stages of the disease.

The METAVASC project pioneers a novel study of the brain vasculature as a key regulator of both early and advanced stages in BrM, challenging the traditional view of the vascular system as merely structural. By following a multifaceted approach – including niche labeling systems, CRISPR and drug screenings, multiplex immunofluorescence, spatial transcriptomics, and functional studies – this project aims to overcome current limitations in understanding BrM biology from a vascular perspective, addressing two key questions: How do vascular components influence cancer cell survival during the initial stages of BrM (Aim 1)? And how does the brain vasculature regulate immune cell recruitment and activation in later stages (Aim 2)? Although immunocompetent BrM mouse models will be critical to address most of the fundamental questions in this project, the validation process in human samples represents an important milestone (Aim 3), as our ultimate goal is to translate our findings into tangible benefits for patients.

In METAVASC, we aim to advance the knowledge of this disease and develop groundbreaking therapies that can transform BrM into preventable and treatable conditions, potentially revolutionizing patient outcomes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOGIPUZKOA
Net EU contribution
€ 1 499 500,00
Address
PASEO DR BEGUIRISTAIN SN
20014 DONOSTIA-SAN SEBASTIAN
Spain
Region
Noreste País Vasco Gipuzkoa
Activity type
Research Organisations
Links
Total cost
€ 1 499 500,00

Beneficiaries (1)